I forbindelse med Zevalin- behandling, som omfatter rituximab og radioaktivt mærket Zevalin, er der i sjældne tilfælde indberettet alvorlige mukokutane reaktioner, herunder Steven- Johnsons syndrom med fatalt udfald.
Severe mucocutaneous reactions, including Stevens-Johnson Syndrome with fatal outcome, have rarely been reported in association with the Zevalin therapeutic regimen, which includes rituximab and radiolabelled Zevalin.